Diese Analysten bewerten die MorphoSys-Aktie
| Analyst | Kursziel | Abstand Kursziel | Datum | |
|---|---|---|---|---|
| UBS AG | 68,00 EUR | - | 06.05.2024 |
Werbung
Kursziele im Branchenvergleich
| Aktie | Buy | Hold | Sell | Ø Kursziel | Abst. Kursziel |
|---|---|---|---|---|---|
| Agennix AG | 0 | 0 | 0 | - | - |
| Amgen Inc. | 0 | 0 | 0 | - | - |
| Bayer | 1 | 8 | 0 | 25,03 EUR | +8,03% |
| BB Biotech AG | 0 | 0 | 0 | - | - |
| Biogen Inc | 0 | 0 | 0 | - | - |
| Biotest AG | 0 | 0 | 0 | - | - |
| Eli Lilly | 1 | 0 | 0 | 994,00 USD | +12,29% |
| EVOTEC SE | 2 | 3 | 0 | 9,90 EUR | +33,03% |
| Johnson & Johnson | 0 | 0 | 0 | - | - |
| MorphoSys | 0 | 1 | 0 | 68,00 EUR | - |
| Novartis AG | 3 | 5 | 1 | 100,25 CHF | +6,41% |
| Pfizer Inc. | 3 | 3 | 0 | 29,20 USD | +22,74% |
| QIAGEN N.V. | 5 | 1 | 0 | 47,50 EUR | +27,24% |
| Roche Holding AG (Inhaberaktie) | 0 | 0 | 0 | - | - |
| Sanofi S.A. | 6 | 3 | 0 | 115,12 EUR | +23,56% |